A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
about
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patientsChemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.A pharmacokinetic study of lipegfilgrastim in children with Ewing family of tumors or rhabdomyosarcoma.Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapyRole of lipegfilgrastim in the management of chemotherapy-induced neutropeniaThe evolving role of biosimilars in haematology-oncology: a practical perspective.Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving ChemotherapyPegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Randomized, double-blind study comparing proposed biosimilar LA-EP2006 with reference pegfilgrastim in breast cancer.Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies.Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer.Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.
P2860
Q26768126-BFB3B3D5-38F5-4052-8F0D-644CF14A13E7Q30975418-7DDB2EA8-C752-48B4-A4B9-3BAA0590F4FEQ33437705-D600F8AD-B91C-47BF-9667-6AA381AAF491Q34941030-D5E55E1E-CF33-4326-8906-764A0B7690A5Q35298321-F7780DB9-03F3-40BB-A196-B99F71B401EAQ36291259-0926C1FE-5C96-4C62-8B1A-9F18CC166CADQ37072872-03207DF2-4FF6-4178-B455-AAD2ED8A967AQ38613025-0126FC94-970D-416B-B73D-2EAFDA3579E9Q38889400-E713F66A-120A-4BA1-A346-8C66A9D582BEQ40889689-04F2677F-AAF4-4A57-869C-918EFE2A20FCQ42363042-1CB99A57-F0F4-4610-9278-D7C6D825DD7CQ50001689-A7C6F76E-2177-46E2-82DA-ECEAA2DFE91EQ50584736-ACEB6C90-72E7-4602-B802-FEB0B821790DQ51584781-4C2C28DB-1312-441C-A2BF-6C56467ABBFE
P2860
A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@ast
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@en
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@nl
type
label
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@ast
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@en
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@nl
prefLabel
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@ast
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@en
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@nl
P2093
P2860
P1476
A randomized, double-blind, ac ...... ving myelosuppressive therapy.
@en
P2093
Anton Buchner
Peter Bias
Reiner Elsässer
P2860
P2888
P304
P356
10.1007/S10549-014-3120-6
P407
P577
2014-09-27T00:00:00Z
P5875
P6179
1001311141